Cost–utility analysis of lecanemab and donanemab for early Alzheimer’s disease in China
10.12206/j.issn.2097-2024.202601011
- VernacularTitle:仑卡奈单抗与多奈单抗治疗早期阿尔茨海默病的成本-效用分析
- Author:
Wei SHAO
1
;
Fei YU
1
;
Ying LIU
1
;
Lixin SHU
2
;
Dan HAN
2
Author Information
1. Liaoning Institute of Basic Medical Sciences, Shenyang 110101, China;School of Pharmacy, Liaoning Vocational College of Medicine, Shenyang 110101, China.
2. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
- Publication Type:Pharmacyadministration
- Keywords:
lecanemab;
donanemab;
Alzheimer’s disease;
cost–utility analysis;
pharmacoeconomics
- From:
Journal of Pharmaceutical Practice and Service
2026;44(7):376-382
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cost–utility of lecanemab and donanemab in the treatment of early Alzheimer’s disease （AD） in China. Methods A Markov model was developed from a societal perspective to compare standard of care （SOC）, lecanemab plus SOC, and donanemab plus SOC in terms of costs, quality-adjusted life years （QALY）, and incremental cost–utility ratios （ICUR）. Deterministic and probabilistic sensitivity analyses were conducted to assess parameter uncertainty. Results Both intervention strategies increased QALY compared with SOC but were associated with substantially higher costs, and neither was cost-effective under the current willingness-to-pay threshold. Conclusion Lecanemab and donanemab may be more appropriately considered within a multi-tiered healthcare reimbursement framework in China rather than relying solely on basic medical insurance.
